Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Ideaya Biosciences Inc (NQ: IDYA )

31.28 +1.29 (+4.30%)
Streaming Delayed Price Updated: 4:00 PM EST, Nov 8, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Ideaya Biosciences Inc

< Previous 1 2 3 4 Next >
This Cognex Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Tuesday
Via Benzinga
Ideaya Biosciences Stock Tumbles Despite Promising Data From Rare Eye Cancer Candidate
IDEAYA Biosciences released interim Phase 2 data that shows promising tumor shrinkage and eye preservation rates. 
Via Benzinga
Oracle To Rally Around 29%? Here Are 10 Top Analyst Forecasts For Tuesday
Via Benzinga
IDYA Stock Earnings: IDEAYA Biosciences Misses EPS for Q2 2024
IDYA stock results show that IDEAYA Biosciences missed analyst estimates for earnings per share the second quarter of 2024. 
Via InvestorPlace
Week In Review: ImmuneOnco Out-Licenses Two Antibodies In $2 Billion Deal
Shanghai ImmuneOnco Biopharma out-licensed global rites (ex-China) for two of its antibodies to Instil Bio of Dallas, Texas. ImmuneOnco will receive an upfront and near-term payments of $50 million,... 
Via Talk Markets
Unveiling 5 Analyst Insights On IDEAYA Biosciences
Via Benzinga
Demystifying IDEAYA Biosciences: Insights From 6 Analyst Reviews
Via Benzinga
The Analyst Verdict: IDEAYA Biosciences In The Eyes Of 6 Experts
Via Benzinga
Why SeaStar Medical Holding Shares Are Trading Lower By Around 34%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
Via Benzinga
Kura Sushi Posts Weak Q3 Results, Joins LegalZoom.com And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session
Via Benzinga
Why Arhaus Shares Are Trading Lower By Around 8%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Via Benzinga
IDEAYA Biosciences Highlights 'Encouraging' Preliminary Efficacy, Safety Profile For Patients With Hard-To-Treat Cancer
IDEAYA Biosciences reports promising Phase 2 clinical data for IDE397 in MTAP-deletion urothelial and NSCLC patients. The study shows a 39% overall response rate, 94% disease control rate, and a... 
Via Benzinga
Corning Increases Sales Forecast, Joins Morphic Holding, Lucid Group And Other Big Stocks Moving Higher On Monday
Via Benzinga
Why Ideaya Biosciences Just Made Its Most Bullish Move Since March
The company is working on a treatment for cancers tied to a genetic alteration called MTAP deletion. 
Via Investor's Business Daily
Why Paramount Global Shares Are Trading Higher By Around 8%; Here Are 20 Stocks Moving Premarket
Via Benzinga
Recap: IDEAYA Biosciences Q4 Earnings
Via Benzinga
The Analyst Verdict: IDEAYA Biosciences In The Eyes Of 8 Experts
Via Benzinga
Critical Insights From IDEAYA Biosciences Analyst Ratings: What You Need To Know
Via Benzinga
IDYA Stock Earnings: IDEAYA Biosciences Misses EPS for Q1 2024
IDYA stock results show that IDEAYA Biosciences missed analyst estimates for earnings per share the first quarter of 2024. 
Via InvestorPlace
Goldman Sachs Maintains Buy Rating for IDEAYA Biosciences: Here's What You Need To Know
Via Benzinga
Chart Of The Day: IDEAYA Biosciences - Oncology Biomedicine
IDEAYA Biosciences, Inc., a synthetic lethality-focused precision medicine oncology company, focuses on the discovery and development of targeted therapeutics for patient populations selected using... 
Via Talk Markets
8 Analysts Have This to Say About IDEAYA Biosciences
Via Benzinga
The Latest Analyst Ratings for IDEAYA Biosciences
Via Benzinga
Why Ideaya Biosciences Stock Is Plummeting Today
Ideaya stock is getting hit hard following a recent press release from the company. 
Via The Motley Fool
Why IDEAYA Biosciences Stock Is Falling During Wednesday's Session
Ideaya Biosciences Inc (NASDAQ: IDYA) shares are trading lower by 11.6% to $24.10 Wednesday morning after the company priced an underwritten public offering of common stock and pre-funded warrants. 
Via Benzinga
Where IDEAYA Biosciences Stands With Analysts
Via Benzinga
7 Analysts Have This to Say About IDEAYA Biosciences
Via Benzinga
Why Owens Corning Shares Are Trading Lower By Around 9%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
Gainers Abri SPAC I, Inc. (NASDAQ: ASPA) shares climbed 127.1% to $28.39. Abri's stockholders approved its proposed business combination with DLQ. 
Via Benzinga
Alphabet, Texas Instruments, CoStar Group And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session
U.S. stock futures traded mixed this morning on Wednesday. Here are some big stocks recording losses in today’s pre-market trading session. 
Via Benzinga
Adobe To Rally Over 14%? Here Are 10 Other Analyst Forecasts For Tuesday
RBC Capital boosted the price target for CareTrust REIT, Inc. (NYSE: CTRE) from $19 to $23. RBC Capital analyst Michael Carroll upgraded the stock from Sector Perform to Outperform. CareTrust REIT... 
Via Benzinga
< Previous 1 2 3 4 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.